Related Experiment Videos
Use of clindamycin in patients with liver disease
Abstract:
Hepatotoxicity has been noted by several investigators during parenteral use of clindamycin, and some have reported that drug half-life is prolonged in the presence of liver disease. We administered 300 mg of clindamycin intravenously at 12-h intervals for 2 days to patients with acute and chronic hepatitis, cirrhosis, and controls to determine whether clindamycin will exacerbate preexisting hepatic dysfunction or whether drug excretion will be delayed in patients with liver disease as compared with controls. Exacerbation of hepatotoxicity was not found in this study. There was a small, but significant, delay in drug elimination between cirrhotics and controls, even after the first dose of clindamycin (P < 0.05); however, half-lives in all categories were in the range usually considered normal. We conclude that clindamycin can be used in liver disease in some circumstances, if proper precautions are exercised.
Insights
Clindamycin does not worsen liver damage in patients with liver disease. While a slight delay in drug elimination was observed in cirrhotics, clindamycin can be used cautiously in liver disease.
Area of Science:
- Pharmacology
- Hepatology
Background:
- Parenteral clindamycin has been associated with hepatotoxicity.
- Drug half-life may be prolonged in patients with liver disease.
Purpose of the Study:
- To evaluate clindamycin's potential to exacerbate hepatic dysfunction.
- To assess if liver disease delays clindamycin excretion.
Main Methods:
- Administered 300 mg clindamycin IV every 12 hours for 2 days.
- Included patients with acute/chronic hepatitis, cirrhosis, and healthy controls.
Main Results:
- No exacerbation of hepatotoxicity was observed.
- A statistically significant, though small, delay in clindamycin elimination occurred in cirrhotics compared to controls.
- Drug half-lives remained within normal ranges for all groups.
Conclusions:
- Clindamycin does not appear to worsen pre-existing liver dysfunction.
- Clindamycin can be considered for use in patients with liver disease under specific conditions and with precautions.
- Careful monitoring is advised due to a potential minor delay in drug elimination in cirrhotic patients.